BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ARO-INHBE readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ARO-INHBE\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06700538-174@assetmemo.bio
DTSTAMP:20261121T005911Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:ARO-INHBE: Phase 1/2 readout est. (NCT06700538)
DESCRIPTION:ARO-INHBE\, phase 1/2\, Obesity.\nStudy: A First-In-Human Study
  of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mell
 itus\nEstimated primary completion: 15 October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/aro-inhbe#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06700538
URL:https://assetmemo.bio/drug/aro-inhbe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859813-174@assetmemo.bio
DTSTAMP:20261121T005911Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:ARO-INHBE: Phase 2 readout est. (NCT07859813)
DESCRIPTION:ARO-INHBE\, phase 2.\nStudy: A Trial to Evaluate the Efficacy a
 nd Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Ste
 atohepatitis\nEstimated primary completion: October 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/aro-inhbe#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07859813
URL:https://assetmemo.bio/drug/aro-inhbe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
